Michael T Lambert1, Laurel A Copeland, Nancy Sampson, Sonia A Duffy. 1. University of Texas Southwestern Medical School at Dallas (UTSWMS), Department of Psychiatry, 5323 Harry Hines Blvd., Dallas, TX 75235-9070, and North Texas Veterans Health Care System, USA. Michael.Lambert2@med.va.gov
Abstract
PURPOSE: This study compared the one-year incidence of new-onset type-2 diabetes mellitus (DM) and changes in weight in patients with a variety of psychiatric diagnoses prescribed olanzapine, risperidone, or quetiapine, compared to a reference group receiving haloperidol and no other antipsychotic medication. RESEARCH DESIGN AND METHODS: Data was abstracted from charts of subjects newly initiated and then maintained for one year on olanzapine (n=112), risperidone (n=100), quetiapine (n=100), and haloperidol (n=100). Baseline and one-year DM status, height, and weight were collected, as well as concurrent psychotropic medications, medical and psychiatric comorbidities. FINDINGS: Using a multivariate model, logistic regression identified a significant association between olanzapine (but not other atypical agents) and the development of diabetes compared to haloperidol over the one-year period (odds ratio 8.4, 95% CI 1.8-38.7). Baseline obesity was independently associated with new-onset DM, but only marginally greater weight gain was found among olanzapine users. CONCLUSIONS: The middle-aged American veterans in this study cohort were highly vulnerable to the diabetogenic effects of olanzapine, but a close correlation with weight change was not found. Patients administered olanzapine should receive careful laboratory monitoring for elevated plasma glucose in addition to weight measurement.
PURPOSE: This study compared the one-year incidence of new-onset type-2 diabetes mellitus (DM) and changes in weight in patients with a variety of psychiatric diagnoses prescribed olanzapine, risperidone, or quetiapine, compared to a reference group receiving haloperidol and no other antipsychotic medication. RESEARCH DESIGN AND METHODS: Data was abstracted from charts of subjects newly initiated and then maintained for one year on olanzapine (n=112), risperidone (n=100), quetiapine (n=100), and haloperidol (n=100). Baseline and one-year DM status, height, and weight were collected, as well as concurrent psychotropic medications, medical and psychiatric comorbidities. FINDINGS: Using a multivariate model, logistic regression identified a significant association between olanzapine (but not other atypical agents) and the development of diabetes compared to haloperidol over the one-year period (odds ratio 8.4, 95% CI 1.8-38.7). Baseline obesity was independently associated with new-onset DM, but only marginally greater weight gain was found among olanzapine users. CONCLUSIONS: The middle-aged American veterans in this study cohort were highly vulnerable to the diabetogenic effects of olanzapine, but a close correlation with weight change was not found. Patients administered olanzapine should receive careful laboratory monitoring for elevated plasma glucose in addition to weight measurement.
Authors: B R Pober; E Wang; S Caprio; K F Petersen; C Brandt; T Stanley; L R Osborne; J Dzuria; B Gulanski Journal: Am J Med Genet C Semin Med Genet Date: 2010-05-15 Impact factor: 3.908
Authors: Almut G Winterstein; Paul Kubilis; Steve Bird; Rhonda M Cooper-DeHoff; Greg A Nichols; Joseph A Delaney Journal: Pharmacoepidemiol Drug Saf Date: 2014-06-12 Impact factor: 2.890
Authors: Ellen M Janssen; Emma E McGinty; Susan T Azrin; Denise Juliano-Bult; Gail L Daumit Journal: Gen Hosp Psychiatry Date: 2015-03-14 Impact factor: 3.238
Authors: Laurel A Copeland; John E Zeber; Chen-Pin Wang; Michael L Parchman; Valerie A Lawrence; Marcia Valenstein; Alexander L Miller Journal: BMC Health Serv Res Date: 2009-07-26 Impact factor: 2.655